<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182907</url>
  </required_header>
  <id_info>
    <org_study_id>6072-001</org_study_id>
    <secondary_id>2017-000070-11</secondary_id>
    <nct_id>NCT03182907</nct_id>
  </id_info>
  <brief_title>Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)</brief_title>
  <acronym>MODIFY III</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to &lt;18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and
      tolerability of bezlotoxumab in children aged 1 to &lt;18 years of age with a confirmed
      diagnosis of Clostridium difficile infection (CDI) who are receiving antibacterial drug
      treatment. The primary hypothesis is that the area under the concentration-time curve from 0
      to infinity (AUC0-inf) of bezlotoxumab after treatment of pediatric participants with
      bezlotoxumab is similar when compared to the AUC0-inf of bezlotoxumab after treatment of
      adults with bezlotoxumab,
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">May 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration time curve of bezlotoxumab</measure>
    <time_frame>Day 1 (2 hrs after infusion), Days 10, 29, 57, and 85</time_frame>
    <description>Area under the concentration time curve from time 0 to infinity (AUC0-inf) of serum bezlotoxumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Percentage of participants experiencing AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuing medication</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants discontinuing study medication due to an AE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile infection (CDI) recurrence</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants who have a CDI recurrence within 12 weeks of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical response</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants with sustained clinical response within 12 weeks of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDI recurrence and sustained clinical response</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants who have a CDI recurrence and who achieve sustained clinical response within 12 weeks of study medication infusion in participants at high risk of CDI recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion-related reactions</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Percentage of participants experiencing 1 or more infusion-related reactions within 24 hours following the start of study medication infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive antibodies to bezlotoxumab</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Percentage of participants with treatment-emergent positive antibodies to bezlotoxumab in serum through 12 weeks following a single dose of bezlotoxumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Bezlotoxumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bezlotoxumab</intervention_name>
    <description>A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.</description>
    <arm_group_label>Bezlotoxumab</arm_group_label>
    <other_name>MK-6072</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At screening has suspected or confirmed CDI, and is receiving or is planning to
             receive a 10- to 21-day course of antibacterial drug treatment for CDI

          -  At study infusion has a diagnosis of CDI confirmed by a diagnostic assay which detects
             the presence of C. difficile toxin in stool, and is still receiving antibacterial drug
             treatment for CDI.

          -  Female is not pregnant, and not breastfeeding; but if of childbearing potential agrees
             to follow contraceptive guidance during the treatment period and for at least 12 weeks
             after the last dose of study treatment

          -  Participant and/or parent or caregiver must be able to read, understand, and complete
             the daily diary

        Exclusion Criteria:

          -  Has an uncontrolled chronic diarrheal illness

          -  Has a known hypersensitivity to bezlotoxumab, its active substance and/or any of its
             excipients

          -  At randomization, their planned course of antibacterial drug treatment for CDI is
             longer than 21 days

          -  At screening has received any listed prohibited prior and concomitant treatments and
             procedures

          -  Has previously participated in this study, has previously received bezlotoxumab, has
             received an experimental monoclonal antibody against C. difficile toxin B, or has
             received a vaccine directed against C. difficile or its toxins.

          -  Has received an investigational study agent within the previous 30 days, or is
             currently participating in or scheduled to participate in any other clinical study
             with an investigational agent during the 12-week study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital - Los Angeles ( Site 0021)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>323-361-5047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center ( Site 0049)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-476-1756</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Colorado ( Site 0013)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago ( Site 0019)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-702-1665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Hospital ( Site 0007)</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>225-765-4365</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Rubenstein Child Health Building ( Site 0034)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-614-2949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center-Floating Hospital for Children ( Site 0046)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-636-0186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester ( Site 0004)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University ( Site 0037)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>314-747-5128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center ( Site 0041)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/ MSCHONY ( Site 0042)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-342-3647</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical Center, University Hospital ( Site 0027)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke University Health System ( Site 0025)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-668-4855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0024)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-636-7499</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center ( Site 0029)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>216-983-6925</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital ( Site 0050)</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>901-595-1475</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center ( Site 0022)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-322-2757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of San Antonio ( Site 0009)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-704-4708</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital ( Site 0001)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital ( Site 0028)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-884-5086</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires. ( Site 2103)</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1199ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5491155688183</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Cordoba ( Site 2102)</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+543513101447</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericordia de Belo Horizonte ( Site 0208)</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-321</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+553132388849</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas da Universidade Federal do Parana ( Site 0203)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554133607938</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pequeno Principe ( Site 0200)</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+554191993340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario da Universidade Federal de Santa Maria ( Site 0209)</name>
      <address>
        <city>Santa Maria</city>
        <state>Rio Grande Do Sul</state>
        <zip>97105-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5555981129912</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia Pediatrica - GRAACC - Unifesp ( Site 0205)</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04039-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+551150808592</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil Instituto de Cardiologia ( Site 2163)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>110131</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157734008</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 2161)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573188372518</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco ( Site 2160)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+572518500014091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno ( Site 2000)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>613 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420532234126</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen ( Site 2001)</name>
      <address>
        <city>Plzen Lochotin</city>
        <state>Plzensky Kraj</state>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420377104330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2. LF UK a FN Motol ( Site 2003)</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420224436420</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenster ( Site 1400)</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+492518352840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg Eppendorf ( Site 1402)</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4940741052720</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 2200)</name>
      <address>
        <city>Szeged</city>
        <state>Csongrad</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3662545330</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem II. sz. Gyermekgyogyaszati Klinika ( Site 2201)</name>
      <address>
        <city>Budapest</city>
        <zip>1094</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3612151380</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet ( Site 2202)</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3614558517</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sabah Womens &amp; Childrens Hospital ( Site 3101)</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88996</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6088522600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur ( Site 3100)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan Kuala Lumpur</state>
        <zip>50300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+60326155555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Tecnologico y de Estudios Superiores de Monterrey ( Site 0502)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0503)</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Federico Gomez ( Site 0501)</name>
      <address>
        <city>Mexico City</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525552289917</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland universitetssykehus ( Site 1501)</name>
      <address>
        <city>Bergen</city>
        <state>Vestfold</state>
        <zip>5053</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4755975200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo universitetssykehus ( Site 1500)</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+4723074593</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Obserwacyjno Zakazny ( Site 2404)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-030</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48523255605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital im. dr W. Bieganskiego w Lodzi ( Site 2400)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422516104</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 2405)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Pomnik Centrum Zdrowia Dziecka ( Site 2406)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48228157384</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga ( Site 1600)</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+35125302724911010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Central EPE. Hospital D. Estefania ( Site 1601)</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-045</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351213126600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 1603)</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+351225084000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase Cluj-Napoca ( Site 2502)</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400348</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40751519421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof. Dr. Matei Bals ( Site 2501)</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40724354456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase si Tropicale Dr. Victor Babes ( Site 2500)</name>
      <address>
        <city>Bucuresti</city>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40723577388</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Boli Infectioase Constanta ( Site 2504)</name>
      <address>
        <city>Constanta</city>
        <zip>900708</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+40723472844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Phoenix Pharma Pty Ltd ( Site 2607)</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27413733832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johese Clinical Research ( Site 2605)</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>1692</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27126641608</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 2602)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1860</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119330270</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sefako Makgatho Health Sciences University ( Site 2603)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27125215633</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Cross War Memorial Children's Hospital ( Site 2601)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27216585369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Deu ( Site 1704)</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus ( Site 1701)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 1703)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 1705)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955012914</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ITCC Barnokologen Astrid Lindgrens Barnsjukhus NKS ( Site 1800)</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Lan [se-01]</state>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46722214431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barncancercentrum ( Site 1801)</name>
      <address>
        <city>Goteborg</city>
        <state>Vastra Gotalands Lan [se-14]</state>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+46313436082</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital ( Site 1900)</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442381206883</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust ( Site 1901)</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+447824519571</phone>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

